奈达铂联合多西紫杉醇治疗晚期非小细胞肺癌的临床观察  

Clinical Observation of Advanced Non-small Cell Lung Canncer Treated with Nedaplatin Plus Docetaxel

作　　者：石永康[1] 田声望[1] 郭玉华[1] 

机构地区：[1]江苏大学附属金坛市人民医院肿瘤科,213200

出　　处：《实用癌症杂志》2012年第3期286-287,291,共3页The Practical Journal of Cancer

摘　　要：目的探讨奈达铂联合多西紫杉醇治疗晚期非小细胞肺癌的疗效和毒性。方法对23例晚期非小细胞肺癌应用奈达铂联合多西紫杉醇治疗,并对其疗效及毒性进行分析。结果奈达铂联合多西紫杉醇治疗晚期非小细胞肺癌的总有效率为39.3%,其中鳞癌有效率为38.5%,腺癌有效率为40.0%,主要不良反应为骨髓抑制、恶心、呕吐,绝大多数患者耐受性良好。结论奈达铂联合多西紫杉醇治疗晚期非小细胞肺癌安全,有效,值得临床推广应用。Objective To investigate the efficacy and toxicity of nedaplatin plus docetaxel on the treatment of advanced non-small cell lung cancer（NSCLC）. Methods Retrospective study was used to analyze the clinical data of 23 eases of NSCLC treated by nedaplatin and doeetaxel. Results The overall response rate of this treatment method was 39.3% ,response rate was 38.5 % for squamous carcinoma,40.0% for adenous carcinoma.. The main side effects were myelosuppression, nausea and vomiting. Almost all the patients could tolerate the side effects. Conclusion The study proves that nedaplatin plus docetaxel regiment is an effective and well to tolerated treatment of NSCLC and is worth being used widely.

关 键 词：多西紫杉醇 奈达铂 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]